Interventional oncology · London
Y-90 radioembolisation (SIRT) - private in London.
A day-case, catheter-delivered dose of yttrium-90 microspheres for liver tumours - HCC, colorectal liver metastases, cholangiocarcinoma and neuroendocrine metastases - done by an interventional oncologist in a unit with a weekly Y-90 service and full hepatobiliary MDT backing.
Why patients choose us
- 01
A dedicated interventional oncology team
Not a general IR list. A named interventional radiologist working with a hepatobiliary MDT, in a unit that runs Y-90 as a weekly service, not an occasional case.
- 02
The right liver-directed therapy for the tumour
SIRT is not always the answer. For some tumours TACE, ablation, resection or systemic therapy is the better call, and we say so before you commit.
- 03
Independent, and free
We are paid by no clinic, so the recommendation is impartial and costs you nothing.
Indicative pricing
What private Y-90 SIRT costs in London.
Indicative ranges across our partner interventional oncology units. Send the imaging and MDT summary and we quote firm all-inclusive figures across two or three options.
In short
A single Y-90 treatment in our London network: £22,000-£38,000 all-inclusive, home the same day.
| Procedure | Indicative range | Typical duration | Turnaround |
|---|---|---|---|
| Second-opinion review of imaging and MDT summary | £350-£650 | 30-45 min | 48 hours |
| Workup angiogram and MAA lung-shunt scan | £4,500-£7,500 | 90-120 min | Same visit |
| Y-90 SIRT, single lobe (TheraSphere or SIR-Spheres) | £22,000-£30,000 | 60-90 min | Day-case / overnight |
| Y-90 SIRT, bilobar sequential (both lobes) | £34,000-£38,000 | 2 sessions | 6-8 weeks apart |
| Radiation segmentectomy (small HCC, high-dose) | £24,000-£32,000 | 60-90 min | Day-case |
| Follow-up MRI or CT liver at 3 months | £650-£1,100 | 30-45 min | 48 hours |
Y-90 pricing is all-inclusive: workup angiogram and MAA scan, the microsphere product (TheraSphere or SIR-Spheres), the treatment procedure, personalised dosimetry, post-treatment PET-CT and the first follow-up MRI at 3 months. Bilobar disease is treated in two sequential sessions.
The problem
The right interventional oncologist, the right microsphere, the right unit.
Y-90 works when the tumour selection, the dosimetry and the MDT plan are right. A one-size-fits-all lobar SIRT in a low-volume unit is not the same procedure, and we make sure you get the difference.
-
Is SIRT even the right treatment?
For a small solitary HCC, resection or ablation is often better. For bilobar disease with a high tumour burden, systemic therapy first can be safer. We say so.
-
Which microsphere, at what dose?
TheraSphere for HCC and radiation segmentectomy, SIR-Spheres for many colorectal cases. Personalised dosimetry, not flat activity, drives the outcome.
-
Booked into a genuine SIRT service?
A named interventional oncologist, a weekly Y-90 list, on-site nuclear medicine and a hepatobiliary MDT - not a monthly favour done between other lists.
The journey
From referral to response scan - what happens, in order.
One team from first message to the 3-month MRI - workup angiogram, MAA scan, Y-90 delivery, post-treatment PET-CT and MDT review.
Phase 1 · Before your procedure
Concierge, off-stage for you
Phase 2 · On the day
A few hours at the unit
Phase 3 · After
Concierge, back on
- 01
Before
You send us the imaging and MDT summary
A short, confidential form. Recent CT or MRI liver, any PET-CT, tumour markers, prior treatments and the MDT outcome if you have it.
- 02
Before
We come back with a recommendation
Within one working day: whether SIRT fits, or whether TACE, ablation or systemic therapy is the better call. Indicative price. An honest read either way.
- 03
Before
Workup angiogram and MAA scan
A hepatic angiogram maps the arterial supply, coils any gastroduodenal branches at risk, and delivers technetium-labelled albumin to measure lung shunt fraction and calculate a personalised dose.
- 04
On the day
Treatment day at the unit
One to two weeks after workup. Arrival, consent and a chat with the interventional radiologist. Local anaesthetic to the groin or wrist, light sedation as needed.
- 05
On the day
The Y-90 delivery
45 to 90 minutes. A microcatheter is advanced selectively into the tumour-feeding artery and Y-90 microspheres are infused under fluoroscopy. Post-treatment PET-CT or bremsstrahlung SPECT confirms distribution.
- 06
On the day
Home the same day or next morning
Most patients go home the same evening. A short overnight stay if the arterial access needs prolonged observation. Radiation precautions are simple and brief.
- 07
After
Imaging follow-up and MDT review
LFTs at 2 and 6 weeks. MRI or CT at 3 months to assess response by mRECIST, then quarterly. A second lobe treatment is planned if the disease is bilobar.
Typical end-to-end: 2-3 weeks from workup to treatment. Response MRI: 3 months. Second lobe if needed: 6-8 weeks later.
When it helps
When Y-90 SIRT is the right step - and when it is not.
The tumours we see most, plus the physiological gates (lung shunt, bilirubin, extrahepatic spread) that mean SIRT is deferred in favour of TACE, ablation, systemic therapy or best supportive care.
-
Hepatocellular carcinoma (HCC), BCLC B or C
Intermediate or advanced HCC unsuitable for resection, transplant or ablation. SIRT is a mainstream option, with equivalence to sorafenib in the SARAH and SIRveNIB trials.
-
Colorectal liver metastases, chemo-refractory
Liver-dominant colorectal metastases progressing on FOLFOX/FOLFIRI or unsuitable for further systemic escalation, per the EPOCH trial.
-
Intrahepatic cholangiocarcinoma
Unresectable intrahepatic cholangiocarcinoma, either as first-line liver-directed therapy or after gemcitabine/cisplatin progression.
-
Neuroendocrine liver metastases
Progressive liver-dominant NET metastases where PRRT is unavailable, unsuitable, or an adjunct to somatostatin analogues is needed.
-
Radiation segmentectomy for small HCC
A very high tumoricidal dose (>190 Gy) delivered to a single segment for solitary HCC under 5 cm, with 5-year survival approaching resection in selected series.
-
Radiation lobectomy and downstaging
Lobar SIRT can induce contralateral hypertrophy over 3-6 months, downstaging borderline patients to resection or transplant.
-
Selected other liver-dominant primaries
Uveal melanoma, breast and sarcoma liver metastases in an MDT context where liver disease drives symptoms or survival.
-
Not right if lung shunt or bilirubin too high
A lung shunt fraction over 20%, bilirubin over 34 micromol/L without a reversible cause, or extensive extrahepatic disease usually excludes SIRT.
Procedure options
SIRT is a family of techniques - and TACE sits beside it.
What each option on the table actually involves - which microsphere, which dose, which delivery. And how SIRT compares to TACE on time to progression, tolerability and cost.
-
TheraSphere (glass Y-90 microspheres)
Boston Scientific glass microspheres, 20-30 microns, high specific activity, low sphere burden. The standard for HCC and radiation segmentectomy in most UK centres.
-
SIR-Spheres (resin Y-90 microspheres)
Sirtex resin microspheres, 20-60 microns, lower specific activity, higher sphere burden. Well-established in colorectal liver metastases per SIRFLOX, FOXFIRE and EPOCH.
-
Workup angiogram and coil embolisation
Prophylactic coiling of the gastroduodenal, right gastric or other extrahepatic branches at risk, so Y-90 does not reflux to the stomach, duodenum or pancreas.
-
MAA scan and lung shunt fraction
Technetium-99m macroaggregated albumin mimics the Y-90 distribution. A gamma camera measures lung shunt (must be under 20%) and confirms no gut uptake before dosing.
-
Personalised dosimetry
Modern MIRD or partition-model dosimetry calculates a personalised activity in gigabecquerels, based on tumour volume, perfused liver volume, lung shunt and tumour-to-normal-liver ratio.
-
Selective, superselective or radiation segmentectomy
Whole-liver, lobar, selective (segmental) or superselective (radiation segmentectomy) delivery, matched to the number and location of tumours.
-
TACE (transarterial chemoembolisation)
The sister technique: doxorubicin or drug-eluting beads plus ischaemic embolisation. Cheaper per session, more sessions typically needed, more post-embolisation syndrome. Better for small, well-defined HCC in some centres.
-
Second-opinion review
A specialist review of your CT, MRI, MDT summary and prior treatments, sometimes the answer is TACE, ablation, or continuing systemic therapy rather than SIRT.
SIRT vs TACE, at a glance
TACE (transarterial chemoembolisation) is cheaper per session but usually needs multiple sessions, works by combining chemotherapy with arterial ischaemia, and often produces a more marked post-embolisation syndrome. SIRT is a single-session, well-tolerated radiation therapy with a longer time to progression on HCC data, and non-inferior overall survival to sorafenib in the SARAH and SIRveNIB trials. The EPOCH trial supports SIRT in chemo-refractory colorectal liver metastases. Radiation segmentectomy at high tumoricidal dose can deliver 5-year survival approaching resection for solitary small HCC.
Our vetted London network
A small panel of interventional oncologists, we picked them.
Consultants with a dedicated interventional-oncology practice at King's College Hospital Private, Royal Free Private Care, Imperial College Healthcare Interventional Radiology Private, HCA London Bridge and UCLH Private. Introductions are made privately, once we understand your case.
Selection criteria
How we choose every interventional oncologist in our network.
-
Interventional radiologists with a dedicated interventional-oncology practice and a weekly Y-90 service
-
Hepatobiliary MDT with hepatology, oncology, surgery, nuclear medicine and radiology at the table
-
On-site nuclear medicine for MAA scans, personalised dosimetry and post-treatment PET-CT or SPECT
-
Both TheraSphere and SIR-Spheres available, so the microsphere is chosen to fit the tumour, not the stock
Outcomes, safety and recovery
What Y-90 achieves, and what to plan for afterwards.
Median overall survival is 12-16 months for BCLC B/C HCC and 8-12 months for chemo-refractory colorectal liver metastases. Radiation segmentectomy for small solitary HCC delivers 5-year overall survival of 60-70% in specialist series. Recovery is measured in days, not weeks.
-
Fatigue and RUQ discomfort for 1-2 weeks
Post-radioembolisation syndrome is milder than TACE. Fatigue, mild right-upper-quadrant ache and low-grade fever settle over 1-2 weeks with paracetamol and rest.
-
Radiation-induced liver disease (REILD)
REILD occurs in around 1-4% and is more likely in patients with cirrhosis, high whole-liver dose or prior chemotherapy. Careful dosimetry and lobar treatment minimise the risk.
-
Non-target embolisation to stomach or duodenum
Rare with modern workup and prophylactic coiling. Presents as gastroduodenal ulceration a few weeks later, treated with high-dose PPI and endoscopic care.
-
Radiation pneumonitis if lung shunt missed
Uncommon with proper MAA assessment. The lung shunt fraction must be under 20% and lung dose kept under 30 Gy per treatment, 50 Gy cumulative.
-
Access-site care after the femoral or radial puncture
A few hours of bed rest for a femoral puncture, less for a radial approach. Simple wound care, watching for haematoma, and no heavy lifting for a week.
-
Simple radiation precautions
Y-90 is a pure beta emitter so external radiation risk is very low. Standard advice: separate bedrooms and toilet hygiene for a few days, and no close contact with pregnant women or young children for a week.
-
Bilirubin and LFT monitoring
Bilirubin, ALT, ALP and albumin at 2 and 6 weeks. A modest transient rise is expected. A sustained rise triggers hepatology review before any second lobe is treated.
-
Response assessment by mRECIST
MRI or CT at 3 months, then quarterly, using modified RECIST for HCC (loss of arterial enhancement) rather than tumour shrinkage alone.
-
Red flags after discharge
Severe abdominal pain, vomiting, high fever, jaundice or black stools, call the unit or attend A&E the same day.
Reading your SIRT report
Your Y-90 report in four parts. Read the last one first.
Whichever microsphere was used, the report the interventional oncologist sends you keeps to the same shape.
A quiet reminder
Interventional oncology language is precise and can read coldly - we translate it for you.
If you would like us to talk you through the report before your MDT review, just ask.
- 01 Workup
Arterial anatomy, coils and lung shunt
Which vessels were mapped, which extrahepatic branches were coiled, and the MAA-derived lung shunt fraction that set your dose ceiling.
- 02 Dosimetry
Activity delivered and target dose
Total activity in gigabecquerels, tumour-absorbed dose in Gy, normal perfused liver dose, and the dosimetry model used (MIRD, partition or voxel-based).
- 03 Findings
Distribution on post-treatment imaging
The Y-90 PET-CT or bremsstrahlung SPECT distribution: where the dose actually landed, whether it matched the target, and any non-target activity.
- 04 Impression
Response plan and second-lobe timing
Read this first: when the follow-up MRI is booked, whether a second lobe is planned, and what your hepatology and oncology follow-up looks like.
Recognised by major UK insurers
Cover for Y-90 SIRT varies by insurer and by indication - usually funded when medically indicated and MDT-recommended. We confirm cover before booking.
Frequently asked
Everything we get asked about Y-90 SIRT.
Quick answers on day-case treatment, repeatability, insurance cover, lung shunt, MDT decisions and recovery.
-
Is Y-90 SIRT an outpatient procedure?
For most patients, yes. The workup angiogram and the Y-90 treatment itself are both day-case procedures, with an optional overnight stay if the arterial access is complex or you live far from the centre. There is no general anaesthetic, just local anaesthetic and light sedation.
-
Can SIRT be repeated if the tumour progresses?
Yes. A second SIRT to the other lobe is a standard bilobar strategy, typically 6-8 weeks after the first. Retreatment of the same lobe is possible in selected patients if dosimetry, liver function and MDT review support it, though the cumulative liver dose is watched carefully to avoid REILD.
-
Will my insurance cover Y-90 radioembolisation?
Most major UK insurers (Bupa, AXA, Vitality, Cigna, Aviva, WPA) fund SIRT for approved indications such as HCC and colorectal liver metastases, on prior authorisation and an MDT recommendation. Cover for less common indications is decided case by case. We confirm cover in writing before booking.
-
Why does the lung shunt fraction matter so much?
Y-90 microspheres lodge in the tumour capillary bed, but a proportion can pass through arteriovenous shunts inside the tumour and reach the lungs. A lung shunt over 20% risks radiation pneumonitis, so the MAA scan is a mandatory safety gate before dosing. A high shunt may exclude SIRT or trigger a reduced dose.
-
Do I need an MDT decision before SIRT?
Yes. Every SIRT candidate goes through a hepatobiliary or upper-GI MDT with hepatology, oncology, surgery, nuclear medicine and interventional radiology. It confirms the diagnosis, rules out better options (resection, transplant, ablation, systemic therapy) and documents the treatment intent (curative segmentectomy, disease control, downstaging).
-
What is recovery like after Y-90?
Most patients feel tired with a mild right-upper-quadrant ache for 1-2 weeks. Paracetamol and rest are usually enough. Work, driving and normal activity are typically resumed within 7-10 days. LFTs are checked at 2 and 6 weeks, and the first response MRI or CT is at 3 months.
Ready to talk to a Y-90 specialist?
Send the imaging and MDT summary. We come back within one working day.
An impartial, unpaid recommendation on whether Y-90 SIRT, TACE, ablation, resection or systemic therapy is the right next step - and, if SIRT fits, an introduction to a named interventional oncologist in London.
Related treatments
Looking for something else?
-
Microwave liver tumour ablation
Percutaneous thermal ablation for small HCC and liver metastases.
Learn more -
NanoKnife (irreversible electroporation)
Non-thermal ablation for tumours near vessels or bile ducts.
Learn more -
Tumour cryoablation
Ice-based ablation for selected liver, kidney and bone tumours.
Learn more -
Immunotherapy infusion clinic
Checkpoint inhibitors and combination systemic therapy for HCC and CRC.
Learn more -
Oligometastasis SBRT
Stereotactic body radiotherapy for a few metastases in one or two organs.
Learn more -
Colorectal cancer
The condition hub for colorectal cancer, from diagnosis to liver-directed therapy.
Learn more